NO321273B1 - Fremgangsmate for selektiv separering og rensing av eikosapentaen- og dokosaheksaensyrer eller deres estere - Google Patents
Fremgangsmate for selektiv separering og rensing av eikosapentaen- og dokosaheksaensyrer eller deres estere Download PDFInfo
- Publication number
- NO321273B1 NO321273B1 NO20003335A NO20003335A NO321273B1 NO 321273 B1 NO321273 B1 NO 321273B1 NO 20003335 A NO20003335 A NO 20003335A NO 20003335 A NO20003335 A NO 20003335A NO 321273 B1 NO321273 B1 NO 321273B1
- Authority
- NO
- Norway
- Prior art keywords
- column
- diatomaceous earth
- silver salt
- silver
- unsaturated fatty
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 235000020669 docosahexaenoic acid Nutrition 0.000 title claims abstract description 20
- 150000002148 esters Chemical class 0.000 title claims abstract description 16
- 230000008569 process Effects 0.000 title claims abstract description 16
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical class CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 title claims abstract 3
- 238000000746 purification Methods 0.000 title claims description 17
- 238000000926 separation method Methods 0.000 title claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 69
- 239000005909 Kieselgur Substances 0.000 claims abstract description 57
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000002904 solvent Substances 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 34
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 34
- 229910052709 silver Inorganic materials 0.000 claims abstract description 18
- 239000004332 silver Substances 0.000 claims abstract description 18
- 239000012736 aqueous medium Substances 0.000 claims abstract description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 99
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 36
- 239000011148 porous material Substances 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical group CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract description 19
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical class [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract description 17
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 35
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 20
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 18
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 18
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 18
- 229910001961 silver nitrate Inorganic materials 0.000 description 17
- 229940090949 docosahexaenoic acid Drugs 0.000 description 16
- 239000002994 raw material Substances 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 14
- 125000004494 ethyl ester group Chemical group 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 11
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 7
- 229940013317 fish oils Drugs 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003378 silver Chemical class 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 2
- 241000269821 Scombridae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18140799 | 1999-06-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20003335D0 NO20003335D0 (no) | 2000-06-26 |
| NO20003335L NO20003335L (no) | 2000-12-29 |
| NO321273B1 true NO321273B1 (no) | 2006-04-10 |
Family
ID=16100230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20003335A NO321273B1 (no) | 1999-06-28 | 2000-06-26 | Fremgangsmate for selektiv separering og rensing av eikosapentaen- og dokosaheksaensyrer eller deres estere |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6313330B1 (de) |
| EP (1) | EP1065196B1 (de) |
| AT (1) | ATE241584T1 (de) |
| CA (1) | CA2311974A1 (de) |
| DE (1) | DE60002952T2 (de) |
| DK (1) | DK1065196T3 (de) |
| NO (1) | NO321273B1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2251429B1 (de) | 2003-12-30 | 2017-03-01 | DSM IP Assets B.V. | Entlüftungsverfahren |
| CA2614473C (en) * | 2005-07-08 | 2016-05-03 | Martek Biosciences Corporation | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| EP2173699A4 (de) * | 2007-06-29 | 2014-04-16 | Dsm Ip Assets Bv | Herstellung und aufreinigung von estern mehrfach ungesättigter fettsäuren |
| EP3187182B1 (de) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon |
| JP5503856B2 (ja) | 2008-09-10 | 2014-05-28 | キユーピー株式会社 | 高度不飽和脂肪酸誘導体の取得方法 |
| WO2010118761A1 (en) | 2009-04-17 | 2010-10-21 | Eolas Science Limited | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
| BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
| EP2424521A4 (de) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | Pharmazeutische zusammensetzungen mit epa und einem kardiovaskulären mittel sowie verwendungsverfahren dafür |
| DK2443246T3 (en) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ie Ltd | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY |
| RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
| CA2873141C (en) * | 2009-12-30 | 2018-05-29 | Adam Kelliher | Simulated moving bed chromatographic separation process |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| GB201111594D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New improved process |
| GB201111591D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Further new process |
| GB201111589D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New modified process |
| GB201111595D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Improved process |
| GB201111601D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New process |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
| EP4342546A3 (de) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Verfahren zur verringerung des risikos von herz-kreislauf-ereignissen bei einem patienten in einer statintherapie |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| GB201300354D0 (en) | 2013-01-09 | 2013-02-20 | Basf Pharma Callanish Ltd | Multi-step separation process |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
| US8802880B1 (en) | 2013-05-07 | 2014-08-12 | Group Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| CN103962091B (zh) * | 2013-11-28 | 2017-01-25 | 大连工业大学 | 一种银离子改性氨基硅胶分离epa和dha的方法 |
| EP2883860B1 (de) | 2013-12-11 | 2016-08-24 | Novasep Process | Chromatografisches Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren |
| WO2015104464A1 (fr) | 2014-01-07 | 2015-07-16 | Novasep Process | Procédé de purification d'acides aminés aromatiques |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US11767491B2 (en) | 2019-03-26 | 2023-09-26 | Nisshin Pharma Inc. | Eicosapentaenoic acid alkyl ester-containing composition and method for producing same |
| CN109912403A (zh) * | 2019-04-18 | 2019-06-21 | 南京市第一医院 | 一种Omega-3制备大电导钙激活钾通道开放剂的方法 |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0347509A1 (de) * | 1988-06-21 | 1989-12-27 | Century Laboratories Inc. | Verfahren zur Extraktion und Reinigung von polyungesättigten Fettsäuren aus Naturquellen |
| JPH028298A (ja) * | 1988-06-17 | 1990-01-11 | Agency Of Ind Science & Technol | イカ内臓からドコサヘキサエン酸及びエイコサペンタエン酸を選択的に分離精製する方法 |
| JPH07242895A (ja) * | 1993-03-16 | 1995-09-19 | Ikeda Shiyotsuken Kk | 高純度エイコサペンタエン酸又はその低級アルコールエステルの分離精製法 |
| JPH09151390A (ja) * | 1995-11-30 | 1997-06-10 | Bizen Kasei Kk | 高度不飽和脂肪酸及びその誘導体の精製方法 |
| JPH10310551A (ja) * | 1997-05-12 | 1998-11-24 | Nippon Wax Polymer Kaihatsu Kenkyusho:Kk | エイコサペンタエン酸又はそのエステルの精製方法 |
-
2000
- 2000-06-19 CA CA002311974A patent/CA2311974A1/en not_active Abandoned
- 2000-06-21 DE DE60002952T patent/DE60002952T2/de not_active Expired - Fee Related
- 2000-06-21 AT AT00113020T patent/ATE241584T1/de not_active IP Right Cessation
- 2000-06-21 DK DK00113020T patent/DK1065196T3/da active
- 2000-06-21 EP EP00113020A patent/EP1065196B1/de not_active Expired - Lifetime
- 2000-06-26 NO NO20003335A patent/NO321273B1/no unknown
- 2000-06-28 US US09/604,766 patent/US6313330B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO20003335D0 (no) | 2000-06-26 |
| ATE241584T1 (de) | 2003-06-15 |
| US6313330B1 (en) | 2001-11-06 |
| CA2311974A1 (en) | 2000-12-28 |
| DE60002952D1 (de) | 2003-07-03 |
| EP1065196A1 (de) | 2001-01-03 |
| DE60002952T2 (de) | 2004-03-11 |
| EP1065196B1 (de) | 2003-05-28 |
| DK1065196T3 (da) | 2003-09-22 |
| NO20003335L (no) | 2000-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO321273B1 (no) | Fremgangsmate for selektiv separering og rensing av eikosapentaen- og dokosaheksaensyrer eller deres estere | |
| ES2733599T3 (es) | Proceso de cromatografía mejorado para recuperar una sustancia o un grupo de sustancias de una mezcla | |
| US6433201B2 (en) | Process for separating and purifying eicosapentaenoic acid or its ester | |
| EP1383854B1 (de) | Trennung von mischungen aus pflanzenöl-triglyceriden durch festbettadsorption | |
| JPH08512336A (ja) | 脂肪酸およびその誘導体のクロマトグラフィーによる分画方法 | |
| CA1157041A (en) | Separation of fatty acid esters | |
| EP3029021A1 (de) | Verfahren zur trennung eines fettlöslichen materials mittels simulierter wanderbettchromatografie und vorrichtung dafür | |
| US4524029A (en) | Process for separating fatty acids | |
| JPH0157159B2 (de) | ||
| JPS5888339A (ja) | エイコサペンタエン酸又はそのエステルとドコサヘキサエン酸又はそのエステルの分離精製方法 | |
| JP2001072993A (ja) | エイコサペンタエン酸およびドコサヘキサエン酸またはそれらのエステルを選択的に分離精製する方法 | |
| WO2001051162A1 (en) | A method for recovering pigments from algal cultures | |
| Hill et al. | Frontal chromatographic techniques in preparative chromatography | |
| JPS6137752A (ja) | 高度不飽和長鎖脂肪酸またはそのエステルの分離精製法 | |
| JP2001303089A (ja) | エイコサペンタエン酸またはそのエステルを分離精製する方法 | |
| JPH0381252A (ja) | 高純度ポリグリセリン脂肪酸エステルの製造方法 | |
| JPH01180849A (ja) | ドコサペンタエン酸またはそのエステルの濃縮分離方法 | |
| US4578223A (en) | Process for separating saturated fatty acids from each other | |
| AU758066B2 (en) | A method for recovering pigments from algal cultures | |
| JPS63243061A (ja) | 高度不飽和長鎖脂肪酸アルキルエステルの分離精製方法 | |
| JP2022538558A (ja) | ペルシーの抽出物 | |
| JPS63295551A (ja) | カロチンの精製方法 | |
| JPS638356A (ja) | 高度不飽和長鎖脂肪酸アルキルエステルの分離精製方法 | |
| JP2000080050A (ja) | 光学異性体の吸着分離方法 | |
| JPH0451541B2 (de) |